MATTERS ARISING

Incidence of RA in people with persistently raised RF

A criticism of the study reported in the Ann Rheum Dis is that age was not taken into account in the evaluation of the probability of development of rheumatoid arthritis (RA) among symptom free subjects with persistently raised rheumatoid factor (RF). The prevalence of RF can be as high as 14.1% in apparently healthy people aged 67–95 (mean age 81).² RF is also 3.5 times more common in healthy elderly subjects (aged >65) than in their younger counterparts.¹ All these factors may alter the natural history of arthritis in elderly patients who have RF either in good health or in a non-arthritic presentation of RA.

The latter is exemplified by a patient admitted at the age of 76 with symptomatic, as well as echocardiographically validated rheumatoid pericarditis in the absence of arthritis. Rheumatoid arthritis latex fixation test (RA LFT) was positive with a titre of 1/160, antinuclear factor (ANF) titre was 1/250, and signs of active inflammatory disease included a platelet count of 750 × 10⁹/l, and an erythrocyte sedimentation rate (ESR) of 98 mm/1st h (Westergren). Arthralgia of the hands and wrists developed for the first time two years later (when she was no longer taking steroids), with a subsequent RA LFT titre of 1/80 and an ANF titre of 1/320 about four months after the onset of arthralgia. Radiography showed narrowing of the joint spaces of the hands 12 months later, but there were as yet no erosions at this stage. Erosions were seen in March 1992, approximately two and a half years after the onset of arthralgia, when the RA LFT titre was 1/160, ANF titre 1/160, platelet count 421 × 10⁹/l, ESR 18 mm/1st h. At her most recent attendance, on 2 February 2000, she was still very active, having continued to receive prednisolone (maximum dose 5 mg/d) continuously since 1989. Her only complaint was a little pain in the left thenar eminence and painful heels. RF was now 768 IU/ml, ANF titre 1/320, platelet count 340 × 10⁹/l, ESR 42 mm/1st h. Antibodies against double stranded DNA had not been reported at any stage.

COMMENT

This case shows a remarkable dissociation between arthritic symptoms and levels of RF, perhaps signifying that when the immune status is altered in older age,¹ the relationship between RF and the natural history of RA might be less clear than it is in younger people.

Author's reply

It is certainly well documented that the incidence of rheumatoid factor (RF) increases with age. However, we are not aware of any study of different RF isotypes in this context, but our own unpublished observation indicates that it is mainly IgM RF that tends to increase in symptom free elderly people.

However, increased incidence of raised RF in elderly people is not relevant to the findings that we published recently in the Ann Rheum Dis.¹ We simply observed increased prevalence and incidence of rheumatoid arthritis (RA) in elderly subjects who had one or more RF isotypes persistently raised, usually IgM and IgA, compared with those with a transient increase in RF or persistent increase in only one RF isotype. There was no significant age difference between these three groups of subjects studied.

Dr Jolobe’s case history simply confirms what has already been often reported previously that an increase of RF often precedes clinical manifestation of RA.¹ It would have been interesting to know about the RF isotype pattern of his patient. We have noted that the pulmonary manifestation of RA is strongly associated with raised IgA RF.²

HELDI VALDIMARSSON
Department of Immunology,
National University Hospital,
Landhúsið, 101 Reykjavik, Iceland

O M P JOLIBE
Department of Medicine for the Elderly,
Tameside General Hospital,
Fountain Street,
Ashton under Lyne OL6 9RW, UK

LETTERS TO THE EDITOR

The HLA-B*2709 subtype in a patient with undifferentiated spondarthrosis

In 1998, in this journal, we reported the cases of two B27 positive patients with undifferentiated spondyloarthropathy (sSpA) and showed that they were expressing the same HLA-B27 allele in the palm of the hand.³ Neither patient had axial disease but showed peripheral manifestations of spondyloarthropathy (SpA), such as peripheral arthritis, peripheral enthesitis, and dactylitis.³

Recently, one of our two patients (No 2) was subtyped and found to be B*2709 positive. As far as we know this subtype has never been found in patients with SpA. DNA typing of HLA class I alleles was performed using a DNA sample prepared from peripheral blood lymphocytes by the salting out procedure.¹ The class 1 ABC SSP UNITRAY low resolution kit (Pel-Freeze) was used. The primer sets amplify all alleles described by the International Nomenclature Committee of WHO in 1995 and in 1997.²

Polymerase chain reaction amplification with sequence-specific primers (PCR-SSP) was used. A control primer pair was present to verify the integrity of the PCR reaction. Molecular typing of B27 was performed automatically with specific analyzers for detection on a DNA automated sequencer (ABI PRISM 377, Perkin Elmer). Data processing and allele assignment were performed automatically with specific analysis software that compares the sequenced results against a sequence library and provides individual allele assignment for each sequence. The HLA-B class 1 high resolution typing of our sample was HLA-B*0801/B*2709 in agreement with the low resolution typing performed by PCR-SSP.

SpA has a strong association with the HLA-B27 molecule. Studies in humans and transgenic rodents suggest a direct involvement of HLA-B27 in the pathogenesis of the disease. Thirteen subtypes of HLA-B27 (B* 01–13) have been described, differing from each other by one or more amino acid changes, mainly in the peptide-binding site. Of these B*2701, 02, 03, 04, 05, 07, 08, and 10 are associated with ankylosing spondylitis (AS) (B*2701–13 are rare, which has precluded assessing their putative association with AS. B*2706 is not associated with AS in South East Asia. However some B*2706 positive patients with AS have been reported in China.⁴ It has been suggested that the B*2706 might protect against SpA. Recently, a study on families in which both B*2704 and B*2706 might protect against SpA. Recently, a study on families in which both B*2704 and B*2706 occurred has suggested that B*2706, although not associated with SpA, does not protect against SpA.

B*2709 has been found in Sardinia and in continental Italy, where the frequency of HLA-B27 in the general population is around 2%. B*2709 accounts for 25% of HLA-B27 subtypes in Sardinia and 3% in continental Italy. D’Amato and coworkers have tested 35 Sardinian patients with AS and 40 Sardinian B27 positive healthy subjects by genomic typing.⁵ None of the patients with AS were found to be B*2709 positive, in contrast with 25% among the healthy controls. The authors suggested that B*2709 is not


4 D’Amato and coworkers have tested 35 Sardinian patients with AS and 40 Sardinian B27 positive healthy subjects by genomic typing. None of the patients with AS were found to be B*2709 positive, in contrast with 25% among the healthy controls. The authors suggested that B*2709 is not

www.annrheumdis.com
Y chromosome microchimerism in rheumatic autoimmune disease

It has been shown that some features of chronic graft-versus-host disease (GVHD) resemble those of other rheumatic autoimmune diseases, such as systemic sclerosis (SSc), Sjögren’s syndrome (SS), and primary biliary cirrhosis (PBC). Furthermore, the development of systemic lupus erythematosus (SLE)-like diseases has been seen in murine models of GVHD. The pathogenesis of rheumatic autoimmune diseases is still unknown. One possibility that has been suggested is that these diseases are associated with pregnancy because of their strong female predilection and, especially in SSc, a peak incidence after parturition. In 1996 Bianchi et al reported that fetal cells could survive in the maternal circulation for up to 27 years after parturition, a phenomenon termed fetal microchimerism. These observations led the hypothesis that persistent fetal cells in the maternal circulation could mediate a graft-versus-host reaction, resulting in autoimmune disease.

Nelson et al have previously carried out a quantitative assay for male DNA in women with SSc and normal women who had delivered at least one son. They indicated that the mean number of male cell DNA equivalents among controls was 0.38 cells/16 ml whole blood and 11.1 among patients with SSc. In addition, Artlett et al have shown Y chromosome-specific sequences in the DNA extracted from peripheral blood in 32 of 69 women with SSc (46%) as compared with 1 of 25 normal women (4%). They also reported that those allo-cells were T lymphocytes and infiltrated lesional skin. These findings support the hypothesis that fetal microchimerism may contribute to the pathogenesis of SSc. However, this is still controversial because Murata et al have recently reported that there is no significant difference in the presence of fetal DNA in peripheral blood between Japanese patients with SSc and healthy women with non-quantitative assay. Here we report further studies of fetal microchimerism in SSc, SLE, and SS.

We assessed for a specific Y chromosome sequence in the DNA extracted from peripheral blood by a nested polymerase chain reaction (PCR) in 20 patients with SSc, 21 patients with SLE, 18 patients with SS, and 41 healthy volunteers. All patients and healthy volunteers were Asian-Japanese women who had delivered at least one son. The nested PCR was done using the primers specific for a part of the Y chromosome sequence, DYZ1, as described previously. The identity of the detected PCR product was confirmed by nucleotide sequencing. The results from healthy volunteers and test groups were compared by Fisher’s exact probability test.

Y chromosome-specific DNA was detected in 10 of the 20 patients with SSc (50%), eight of 41 healthy volunteers (20%, p=0.017), and six of 18 patients with SS (33%). No Y chromosome-specific DNA was detected in any of the patients with SLE (table 1). The DYZ1 was most commonly found in Barnett’s type III (four of five). The DYZ1 positive patients with SSc also had a variety of antibodies including anti-RNP, anti-mitochondrial, and anti-smooth muscle antibodies that may reflect polyclonal activation of immune cells. Anticentromere antibodies were detected more commonly in the DYZ1 negative group (eight of 10). All three patients with SSc who had PBC were DYZ1 positive and had anticentromere antibodies (table 2).

Our data confirm that male DNA is found more commonly in women with SSc than in normal women. Interestingly, DYZ1 was not detected in patients with SLE and there was no significant difference between patients with SS and healthy volunteers. These data suggest that fetal microchimerism may be a phenomenon which is strongly associated with the pathogenicity of SSc and not with the related autoimmune diseases, SLE and SS.

Table 1 Patients’ characteristics

<table>
<thead>
<tr>
<th></th>
<th>SSc</th>
<th>SLE</th>
<th>SS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td>20</td>
<td>21</td>
<td>18</td>
</tr>
<tr>
<td>Age (years, mean (range))</td>
<td>56.1 (44-74)</td>
<td>50.2 (34-82)</td>
<td>54.8 (27-74)</td>
</tr>
<tr>
<td>Duration of illness (years, mean (range))</td>
<td>10.2 (1-26)</td>
<td>11.9 (1-24)</td>
<td>8.7 (1-19)</td>
</tr>
<tr>
<td>DYZ1 positive (% of normal)</td>
<td>10 (50)</td>
<td>0 (0)</td>
<td>6 (33)</td>
</tr>
</tbody>
</table>

*p<0.017, systemic sclerosis (SSc) vs. healthy volunteers.

**p=0.028, healthy volunteers and systemic lupus erythematosus (SLE). SS= Sjögren’s syndrome.

Table 2 Comparison of clinical findings of DYZ1 positive and negative systemic sclerosis groups

<table>
<thead>
<tr>
<th>DYZ1</th>
<th>Positive (n=10)</th>
<th>Negative Total (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barnett’s type</td>
<td>I</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Autoantibodies</td>
<td>Anti-nuclear</td>
<td>Topoisomerase I</td>
</tr>
<tr>
<td></td>
<td>factor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>15</td>
</tr>
<tr>
<td>ss-A(Re)</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>ss-B(La)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>RA</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>ssDNA</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Mitochondria</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Smooth muscle</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

*pBC = primary biliary cirrhosis.
found increased concentrations of suPAR in disease.

patients with disseminated malignant enzyme plasmin, which plays a part in tissue uPA) catalyzes the formation of the proteolytic action of uPA is localised and intensified by a sensitive, other symptomatic joints, taken

Tender joints (of 28) 6 (3–20) 4 (0–17)
Swollen joints (of 28) 4 (1–8) 2 (0–10)

Table 1 Period average values of corresponding paraclinical and clinical variables of 16 patients with rheumatoid arthritis followed up prospectively and subsequently divided into two groups with or without progressive erosive changes on radiographs. Values are medians with range

<table>
<thead>
<tr>
<th></th>
<th>No erosive progression (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>suPAR (mg/l)</td>
<td>1.03 (0.56–2.09)*</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>11.0 (4.2–29.5)</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>16 (7–58)</td>
</tr>
<tr>
<td>Tender joints (of 28)</td>
<td>4 (0–17)</td>
</tr>
<tr>
<td>Swollen joints (of 28)</td>
<td>2 (0–10)</td>
</tr>
</tbody>
</table>

The study group comprised 11 women and five men with a median age of 53.5 years (range 25–80) and a median disease duration of 57 months (range 5–360). Fifteen patients were rheumatoid factor positive and 10 had bony erosions on pre-study radiographs. Antirheumatic treatment included methotrexate (11 patients), hydroxychloroquine (two), sulfasalazine (one), and low dose steroids (eight). Clinical evaluation and measurement of suPAR, erythrocyte sedimentation rate (ESR), and C reactive protein (CRP) were done a median number of three times, and the time interval between radiographs was a median of 22 months.

Table 1 shows the results of the study. We found significantly higher suPAR concentrations (p<0.05) in plasma from those patients with RA whose x ray findings showed disease progression than in the patients who had no radiographic signs of progression, but the differences in ESR, CRP, and clinical variables were not significantly different.

This study was a pilot study in a clinical setting and conclusions must be drawn cautiously. The main problems, apart from the small number of patients, are, firstly, that in some of the patients pre-study radiographs were one to two years old. However, this would tend to diminish the differences found between the erosive progressive and non erosive progressive groups as patients in remission, or with low activity in the study period, could be classified as progressive due to previous activity. Secondly, another possible bias, tending to increase the difference in suPAR between the two groups in this study, is that patients with high clinical activity would probably have had more extensive x ray examinations, increasing the chance of finding new erosions. We did not, however, find a difference in the number of radiographically investigated joints between our two groups of patients.

In conclusion, we find that this study indicates that plasma suPAR may be an easily accessible plasma marker of erosive progression in RA, and further studies on the subject are warranted.

**CORRECTION**


The Editor of the Annals regrets that we inadvertently published a reply to Dr Barnsley from Drs Ferrari and Russell that contained some misinformation, and offers his apologies to Dr Barnsley.

Possibly, Drs Ferrari and Russell were confusing Dr Barnsley with someone else. Firstly, Dr Barnsley is a man and not a woman, as they stated. Secondly, Dr Barnsley did not attend the World Whiplash Congress in Vancouver and has not read the transcripts of it and thus could not be, as Drs Ferrari and Russell commented, “well aware of an impressive study presented there”.

(No corrections appear in the journal story already appear on the Annals web page (www.annrheumdis.com) and are linked to the original publication.)
Incidence of RA in people with persistently raised RF

O M P JOLOBE

Ann Rheum Dis 2000 59: 654
doi: 10.1136/ard.59.8.654

Updated information and services can be found at:
http://ard.bmj.com/content/59/8/654.1

These include:

References
This article cites 6 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/59/8/654.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/